Clinical trials: Esophageal Adenocarcinoma
Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
- Trial name
- NCT05954312
- Testing
- VVD-130037, Docetaxel, Paclitaxel
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 290 people
- Sponsor
- Vividion Therapeutics, Inc.
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT00964080
- Testing
- MBP-426/Leucovorin/5-FU
- Where
- 5 sites in United States, Georgia
- Volunteers
- 62 people
- Sponsor
- Mebiopharm Co., Ltd
Gastroesophageal-junction Cancer, Esophageal Cancer
Registry for Esophageal and Gastroesophageal Junction Cancer
The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer/GEJ cancer.
- Trial name
- NCT06558786
- Testing
- EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06340711
- Testing
- OBP-301, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
OESOPHAGO-GASTRIC CARCINOMA
Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
Oesophagogastric Cancer and Hypoxia: Oesophagogastric cancer is a significant global burden, with 1.7 million new cases per year. It is well known that survival from oesophagogastric cancer is poor.
- Trial name
- HYDRA (NCT06669663)
- Testing
- Pimonidazole hydrochloride (Hypoxyprobe™-1)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Early Stage Esophageal Adenocarcinoma, Barrett Esophagus
Endoscopic Therapy of Early Cancer in Barretts Esophagus
This study is being done to see if treatment for esophageal cancer can be done using endoscopy for patients ineligible for surgical or radiological therapy.
- Trial name
- NCT00217087
- Testing
- Endoscopic Mucosal Resection, Photodynamic Therapy
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Oesophageal Carcinoma, Gastric Adenocarcinoma
Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers
This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.
- Trial name
- DELOGAST (NCT03246516)
- Testing
- Questionnaire
- Where
- 10 sites in France
- Volunteers
- 258 people
- Sponsor
- University Hospital, Lille
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT01333033
- Testing
- Oxaliplatin, Leucovorin Calcium, Fluorouracil
- Where
- 68 sites in United States
- Volunteers
- 257 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Barrett Esophagus, Barretts Esophagus With Dysplasia
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area…
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
- Trial name
- SWAT-BE (NCT05530343)
- Testing
- Seattle protocol, WATS3D brushings
- Where
- 14 sites in United States
- Volunteers
- 2,298 people
- Sponsor
- University of Colorado, Denver
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Study of FMT Combined With Nivolumab in Gastric Cancer
This study is a single-arm, single center study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules XBI-302 combined with Nivolumab in the treatment of anti-PD-1/L1 resistant gastric cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma, Esophagus Adenocarcinoma
- Trial name
- NCT05001360
- Testing
- XBI-302 + Nivolumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 802 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastrointestinal Cancer
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
This is a phase 2, randomized, double blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in…
- Trial name
- NCT00583674
- Testing
- AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin
- Volunteers
- 171 people
- Sponsor
- Amgen
Oesophageal Adenocarcinoma, Tumor Microenvironment
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
- Trial name
- MEMENTO (NCT06687876)
- Testing
- Metformin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Amsterdam UMC, location VUmc
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.